JP2024529457A5 - - Google Patents
Info
- Publication number
- JP2024529457A5 JP2024529457A5 JP2024505007A JP2024505007A JP2024529457A5 JP 2024529457 A5 JP2024529457 A5 JP 2024529457A5 JP 2024505007 A JP2024505007 A JP 2024505007A JP 2024505007 A JP2024505007 A JP 2024505007A JP 2024529457 A5 JP2024529457 A5 JP 2024529457A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- composition according
- bacteria
- attenuated bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21188352.5 | 2021-07-28 | ||
| EP21188352.5A EP4124342A1 (en) | 2021-07-28 | 2021-07-28 | Cancer therapy with live attenuated bacteria |
| PCT/EP2022/071198 WO2023006879A1 (en) | 2021-07-28 | 2022-07-28 | Cancer therapy with live attenuated bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529457A JP2024529457A (ja) | 2024-08-06 |
| JP2024529457A5 true JP2024529457A5 (cg-RX-API-DMAC7.html) | 2025-05-21 |
Family
ID=77126585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505007A Pending JP2024529457A (ja) | 2021-07-28 | 2022-07-28 | 生弱毒化細菌を用いたがん療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12171791B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4124342A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024529457A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117729929A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022318153A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226844A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006879A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4124342A1 (en) * | 2021-07-28 | 2023-02-01 | Prokarium Limited | Cancer therapy with live attenuated bacteria |
| CN118045167A (zh) * | 2024-02-18 | 2024-05-17 | 绍兴越然生物医药科技有限公司 | 抗肿瘤复合疫苗 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| ES2039229T3 (es) | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
| US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
| GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
| WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
| US20070298012A1 (en) | 2003-12-16 | 2007-12-27 | Ivan King | Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| EP2254902A1 (en) | 2008-02-05 | 2010-12-01 | Æterna Zentaris GmbH | Recombinant bacteria with e. coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof |
| GB0900350D0 (en) | 2009-01-09 | 2009-02-11 | Cambridge Entpr Ltd | Formulations of viable bacteria for oral delivery |
| DK2988762T3 (en) * | 2013-04-25 | 2018-07-16 | Vaximm Ag | SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1 |
| EP2801364A1 (en) | 2013-05-07 | 2014-11-12 | Centre Hospitalier Universitaire Vaudois (CHUV) | Salmonella strain for use in the treatment and/or prevention of cancer |
| EP3495469A1 (en) | 2017-12-07 | 2019-06-12 | Prokarium Limited | Vaccine compositions ii |
| KR20210113632A (ko) * | 2019-01-07 | 2021-09-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 암을 치료하는 방법 |
| EP4124342A1 (en) * | 2021-07-28 | 2023-02-01 | Prokarium Limited | Cancer therapy with live attenuated bacteria |
-
2021
- 2021-07-28 EP EP21188352.5A patent/EP4124342A1/en not_active Withdrawn
-
2022
- 2022-07-28 WO PCT/EP2022/071198 patent/WO2023006879A1/en not_active Ceased
- 2022-07-28 JP JP2024505007A patent/JP2024529457A/ja active Pending
- 2022-07-28 CN CN202280052978.5A patent/CN117729929A/zh active Pending
- 2022-07-28 EP EP22757290.6A patent/EP4376861A1/en active Pending
- 2022-07-28 US US18/559,543 patent/US12171791B2/en active Active
- 2022-07-28 AU AU2022318153A patent/AU2022318153A1/en active Pending
- 2022-07-28 CA CA3226844A patent/CA3226844A1/en active Pending
-
2024
- 2024-11-07 US US18/940,334 patent/US20250064866A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sedighi et al. | Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities | |
| Cao et al. | Bacteria and bacterial derivatives as drug carriers for cancer therapy | |
| Zheng et al. | Targeted cancer therapy using engineered Salmonella typhimurium | |
| Lee et al. | Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial | |
| Patyar et al. | Bacteria in cancer therapy: a novel experimental strategy | |
| JP2019504105A5 (cg-RX-API-DMAC7.html) | ||
| Benitez et al. | Mycobacterium bovis BCG in metastatic melanoma therapy | |
| Garnett-Benson et al. | Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities | |
| JP2016506413A5 (cg-RX-API-DMAC7.html) | ||
| CN105407901A (zh) | 癌症治疗 | |
| JP2020511139A5 (cg-RX-API-DMAC7.html) | ||
| JP2024512775A5 (cg-RX-API-DMAC7.html) | ||
| CN110248671A (zh) | 包含溶瘤痘病毒和nk细胞的治疗剂及其在治疗肿瘤和/或癌症的药物中的应用 | |
| Barni et al. | A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites | |
| JP2018509423A5 (cg-RX-API-DMAC7.html) | ||
| Shi et al. | Systematic review on the role of the gut microbiota in tumors and their treatment | |
| Zhao et al. | Biomimetic “Trojan Horse” delivery of traditional Chinese Medicine with immunogenic hybrid vesicles of bacterial outer membrane and tumor cell membrane for synergistic chemo-immunotherapy of liver cancers | |
| Shahbaz et al. | Current advances in microbial-based cancer therapies | |
| JP2020507332A5 (cg-RX-API-DMAC7.html) | ||
| US20200237904A1 (en) | Methods and Compositions Useful for Treating Cancer | |
| Hernandez-Alcoceba et al. | Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives | |
| Yang et al. | Oncolytic virus for cancer immunotherapy | |
| CN106075453A (zh) | 一种抗肿瘤药物制剂组合 | |
| Khan et al. | Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer | |
| JP2023552383A5 (cg-RX-API-DMAC7.html) |